As­traZeneca gets in on RNA game with Mi­NA re­search col­lab­o­ra­tion

Two months af­ter No­var­tis spent near­ly $10 bil­lion on The Med­i­cines Com­pa­ny’s RNA-based cho­les­terol drug, As­traZeneca will try to co-de­vel­op its own RNA-based meta­bol­ic …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.